Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

G Middleton; P Silcocks; T Cox; J Valle; J Wadsley; D Propper; F Coxon; P Ross; S Madhusudan; T Roques; D Cunningham; S Falk; N Wadd; M Harrison; P Corrie; T Iveson; Robinson A Anus; K McAdam; M Eatock; J Evans; C Archer; T Hickish; A Garcia-Alonso; M Nicolson; W Steward; A Anthoney; W Greenhalf; V Shaw; E Costello; D Naisbitt; R Rawcliffe; G Nanson; J Neoptolemos

doi:10.1016/S1470-2045(14)70236-0

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

G Middleton, P Silcocks, T Cox, J Valle, J Wadsley, D Propper, F Coxon, P Ross, S Madhusudan, T Roques, D Cunningham, S Falk, N Wadd, M Harrison, P Corrie, T Iveson, Robinson A Anus, K McAdam, M Eatock, J EvansC Archer, T Hickish, A Garcia-Alonso, M Nicolson, W Steward, A Anthoney, W Greenhalf, V Shaw, E Costello, D Naisbitt, R Rawcliffe, G Nanson, J Neoptolemos

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	829-840
Number of pages	11
Journal	The Lancet Oncology
Volume	15
Issue number	8
DOIs	https://doi.org/10.1016/S1470-2045(14)70236-0
Publication status	Published - Jul 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(14)70236-0

Cite this

Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., Cunningham, D., Falk, S., Wadd, N., Harrison, M., Corrie, P., Iveson, T., Anus, R. A., McAdam, K., Eatock, M., ... Neoptolemos, J. (2014). Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. The Lancet Oncology, 15(8), 829-840. https://doi.org/10.1016/S1470-2045(14)70236-0

@article{2dfb5fdac7134541b6f086a4e62e88ab,

title = "Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial",

author = "G Middleton and P Silcocks and T Cox and J Valle and J Wadsley and D Propper and F Coxon and P Ross and S Madhusudan and T Roques and D Cunningham and S Falk and N Wadd and M Harrison and P Corrie and T Iveson and Anus, {Robinson A} and K McAdam and M Eatock and J Evans and C Archer and T Hickish and A Garcia-Alonso and M Nicolson and W Steward and A Anthoney and W Greenhalf and V Shaw and E Costello and D Naisbitt and R Rawcliffe and G Nanson and J Neoptolemos",

year = "2014",

month = jul,

doi = "10.1016/S1470-2045(14)70236-0",

language = "English",

volume = "15",

pages = "829--840",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier BV",

number = "8",

}

Middleton, G, Silcocks, P, Cox, T, Valle, J, Wadsley, J, Propper, D, Coxon, F, Ross, P, Madhusudan, S, Roques, T, Cunningham, D, Falk, S, Wadd, N, Harrison, M, Corrie, P, Iveson, T, Anus, RA, McAdam, K, Eatock, M, Evans, J, Archer, C, Hickish, T, Garcia-Alonso, A, Nicolson, M, Steward, W, Anthoney, A, Greenhalf, W, Shaw, V, Costello, E, Naisbitt, D, Rawcliffe, R, Nanson, G & Neoptolemos, J 2014, 'Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial', The Lancet Oncology, vol. 15, no. 8, pp. 829-840. https://doi.org/10.1016/S1470-2045(14)70236-0

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. / Middleton, G; Silcocks, P; Cox, T et al.
In: The Lancet Oncology, Vol. 15, No. 8, 07.2014, p. 829-840.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

AU - Middleton, G

AU - Silcocks, P

AU - Cox, T

AU - Valle, J

AU - Wadsley, J

AU - Propper, D

AU - Coxon, F

AU - Ross, P

AU - Madhusudan, S

AU - Roques, T

AU - Cunningham, D

AU - Falk, S

AU - Wadd, N

AU - Harrison, M

AU - Corrie, P

AU - Iveson, T

AU - Anus, Robinson A

AU - McAdam, K

AU - Eatock, M

AU - Evans, J

AU - Archer, C

AU - Hickish, T

AU - Garcia-Alonso, A

AU - Nicolson, M

AU - Steward, W

AU - Anthoney, A

AU - Greenhalf, W

AU - Shaw, V

AU - Costello, E

AU - Naisbitt, D

AU - Rawcliffe, R

AU - Nanson, G

AU - Neoptolemos, J

PY - 2014/7

Y1 - 2014/7

U2 - 10.1016/S1470-2045(14)70236-0

DO - 10.1016/S1470-2045(14)70236-0

M3 - Article

SN - 1470-2045

VL - 15

SP - 829

EP - 840

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 8

ER -